Founded in 2016, Arctoris Ltd has developed the world’s first fully automated, robotic laboratory for drug discovery. Ulysses, its fully automated drug discovery platform, uses advanced cellular and molecular biology techniques to validate new ideas for drug discovery programmes.
The platform brings together robotics, artificial intelligence (AI) and blockchain to generate drug discovery milestones including target identification, candidate characterisation and dataset generation for AI model validation. Arctoris’s pairing of computational techniques with wet-lab automation reduces cycle times, decreases attrition rates and makes drug discovery success more likely.
Tom Fleming, a chemical biologist, is the Co-Founder and Chief Operating Officer of Arctoris. Tom is responsible for overseeing the company’s team, technologies and expansion. He became an SME Leader in 2019 and has used support from the programme to help scale up the company and deliver drug discovery successes.For his work in the life sciences, he has been recognised by the European Laboratory Research & Innovation Group with the inaugural ECP Impact Award.
Arctoris now has its own drug discovery pipeline as well as creating partnerships with other biotech, pharma and AI companies to develop their work. Its patented proprietary technologies have led to joint ventures with AI companies and research contracts with biotech and pharma on three continents, enabling them to bring new medicines to patients much faster.
Associated Programme
